RAC1

Ras-related C3 botulinum toxin substrate 1 · P63000 · RAC1 on Sugi Atlas →

11,059 patent compounds predicted against RAC1, 6,380 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sanguinarium (SCHEMBL43290)	1.00	6/20
Sanguinarium (SCHEMBL123241)	0.97	6/20
Sanguinarium (SCHEMBL454298)	0.86	6/20
Fagaridine (SCHEMBL108986)	0.76	6/20
SCHEMBL543021	0.55	6/20
SCHEMBL1521201	0.39	6/20
Sanguinarium (SCHEMBL1463519)	0.84	5/20
Hydrochloric Acid (SCHEMBL424548)	0.62	5/20
SCHEMBL424549	0.61	5/20
Hydrochloric Acid (SCHEMBL436618)	0.60	5/20
Chelerythrine (SCHEMBL195109)	1.00	4/20
Chelerythrine (SCHEMBL288915)	0.98	4/20
Chelerythrine (SCHEMBL288916)	0.95	4/20
Chelerythrine (SCHEMBL513051)	0.90	4/20
SCHEMBL215619	0.73	4/20
Nitidine (SCHEMBL420918)	0.71	4/20
SCHEMBL147920	0.71	4/20
Nitidine (SCHEMBL164193)	0.70	4/20
SCHEMBL195376	0.69	4/20
SCHEMBL196289	0.69	4/20

Clinical trials — most relevant to RAC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1/PHASE2	RECRUITING
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas	PHASE2	COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Simvastatin in Secondary Progressive Multiple Sclerosis	PHASE2	COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	PHASE1	ACTIVE_NOT_RECRUITING
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas	PHASE1	COMPLETED
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Prevalence and Characterization of Pain in RASopathies	nan	UNKNOWN
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
RASopathy Biorepository	nan	RECRUITING
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Evaluation of NF1 and Scoliosis Patients	nan	COMPLETED
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)	nan	RECRUITING
Gait in Rare Diseases	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Immune Cell Response to Stimuli	nan	RECRUITING
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a RAC1 binder may also engage these)

Protein	Name	Similarity
P62999	—	1.000	P62999 →
Q6RUV5	—	1.000	Q6RUV5 →
P63001	—	1.000	P63001 →
P62998	—	1.000	P62998 →
P40792	—	0.999	P40792 →
RAC2	Ras-related C3 botulinum toxin substrate 2	0.996	landscape →
RAC3	Ras-related C3 botulinum toxin substrate 3	0.995	landscape →
P60764	—	0.995	P60764 →
P48554	—	0.994	P48554 →
Q9TU25	—	0.992	Q9TU25 →
Q05144	—	0.990	Q05144 →
O88931	—	0.988	O88931 →
A0A286QZ36	—	0.987	A0A286QZ36 →
P48148	—	0.987	P48148 →
P61589	—	0.987	P61589 →
P24406	—	0.986	P24406 →
Q9C3Y4	—	0.986	Q9C3Y4 →
Q03206	—	0.986	Q03206 →
Q22038	—	0.983	Q22038 →
RHOA	Transforming protein RhoA	0.983	landscape →
P61585	—	0.983	P61585 →
Q7T2E8	—	0.982	Q7T2E8 →
Q6NUX8	—	0.981	Q6NUX8 →
P01122	—	0.980	P01122 →
Q1RMJ6	—	0.979	Q1RMJ6 →
Q9QUI0	—	0.978	Q9QUI0 →
CDC42	Cell division control protein 42 homolog	0.978	landscape →
P60766	—	0.978	P60766 →
Q9PSX7	—	0.978	Q9PSX7 →
P60952	—	0.977	P60952 →